Month: July 2023

Highlights:Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial to assess the pharmacokinetics and tolerability of IHL-42X The trial will include 116 participants at CMAX Clinical Research in South Australia and will be managed by Novotech Data from the clinical trial will be a critical component of future marketing submissions for IHL-42X for treatment of OSA The trial will be conducted in parallel to the IND opening and pivotal Phase 2/3 clinical trial OSA is highly prevalent, affecting approximately 30 million adults in the United States alone and there are no registered prescription drugs available to patients for the treatment of OSA The design of the BA/BE trial is consistent with FDA recommendations as part of the required...

JOHNS CREEK, Ga., July 06, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: Ebix), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare, and e-learning industries, today provided a strategic update, detailing the multiple paths it is pursuing to achieve the stated aspirational goal of being a debt-free company in 2023. The Company declared a multi-pronged plan towards achieving the aspirational goal –The Company announced that it is progressing forward diligently with its plan to complete an initial public offering (IPO) of its EbixCash subsidiary in India. In accordance with the directions and regulations of the Indian regulators, EbixCash intends to announce a IPO listing date publicly as soon as it has the requisite approvals in place. Ebix also announced that it...

In relation to Landsbankinn’s covered bond auction yesterday, was a covered bond exchange offering where holders of the series LBANK CB 23 could sell the covered bonds in the series against covered bonds bought in the auction at a predefined clean price of 98.663. The covered bond exchange offering results in Landsbankinn buying ISK 1,980m in the series LBANK CB 23. Settlement will take place on 12 July 2023.

Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th Annual CAR-TCR Summit WORCESTER, Mass., July 06, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that members of its management team will participate in the 2ndIn Vivo Engineering of Therapeutic Cells Summit, scheduled to take place from July 10-12, 2023, and the 8th Annual CAR-TCR Summit, scheduled to take place from August 29 – September 1, 2023, both in Boston, MA. Event details are as follows: 2ndIn Vivo Engineering of Therapeutic Cells Summit Date & Time: July 11, 2023, at 11:00...

SANTA CLARA, Calif., July 06, 2023 (GLOBE NEWSWIRE) — SiTime Corporation (Nasdaq: SITM), the precision timing company, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023, after market close. Rajesh Vashist, SiTime’s chief executive officer, and Art Chadwick, chief financial officer, will broadcast a conference call at 2:00 p.m. Pacific Time to discuss the company’s results. Analysts and investors are invited to join the conference call using the following information: Date: Wednesday, August 2, 2023Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)Live webcast: Click HereRegister for dial-in number: Click Here Advanced registration is required for dial-in participants. Please complete the linked registration form above to receive a dial-in number and dedicated PIN for accessing the conference...

CEO Provides Brief Market Commentary GLYFADA, Greece, July 06, 2023 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today that it has repurchased 362,161 common shares, or approximately 2% of its issued and outstanding shares, at an average price of approximately $4.35 per share pursuant to its previously announced share repurchase program. The average share repurchase price represents approximately a 11.2% discount from the closing price of July 5, 2023. Moreover, the Company entered into a 12-month bareboat charter agreement with an unaffiliated third party in Japan for a 2011-built Newcastlemax dry bulk vessel of 207,855 dwt built at Nantong COSCO KHI Ship Engineering Co Ltd (NACKS). Pursuant to the terms of the bareboat charter, Seanergy has advanced a down payment...

PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second quarter financial results prior to market open on Thursday, August 3, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 am PT / 8:30 am ET. Management will provide an update on the Company’s commitment to commercial performance and ongoing clinical data demonstrating positive patient outcomes for ProSomnus’s patient-preferred, first-line precision oral appliance therapy for the significant patient population afflicted with OSA. Investor Call Dial-In InformationInterested parties may register for the conference call using the following link ProSomnus Q2 2023 Conference...